IGF2BP3 and lung cancer: Although one shortcoming of the present study is that we were not able to determine auto-antibodies in the study population, highly immunogenic peptides derived from IGF2BP3 that can induce tumor-reactive and human leukocyte antigen (HLA)-A2 (A*02:01)-restricted cytotoxic T lymphocytes (CTL) were previously identified in lung cancer patients, suggesting that this protein can represent an important target for therapeutic vaccines [24].